Want to join the conversation?
$AGN will also pay Akarna potential clinical, regulatory and commercial milestone payments related to AKN-083, its lead development compound. AKN-083 is in development for treating Non-Alcoholic Steatohepatitis, a severe type of non-alcoholic fatty liver disease.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.